Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

Report documents

1. Extract of dossier assessment

   Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   01.04.2014

   Document type

   PDF document, 140 kB, EN, not accessible

   Download file : Extract of dossier assessment (PDF document, 140 kB, EN, not accessible)
2. Dossier assessment

   Drug combination of emtricitabine, rilpivirine and tenofovir disoproxil (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   published on

   01.04.2014

   Document type

   PDF document, 329 kB, DE, not accessible

   Download file : Dossier assessment (PDF document, 329 kB, DE, not accessible)

Press releases

Additional information

Project details

Project no.

A14-03

Commission

Commission awarded on 02.01.2014 by the Federal Joint Committee (GBA).

Report type

Dossier assessment

Status

Commission completed

Department/Division

Drug Assessment

Topic

Immune system and infections

Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

1. Dossier assessment

   Emtricitabine/rilpivirine/tenofovir disoproxil - Benefit assessment according to § 35a Social Code Book V (dossier assessment)

   Project no.

   A12-02

   Last updated

   16.04.2012

   Status: Commission completed